Tag: Mirati Therapeutics

Home / Mirati Therapeutics

Categories

Adagrasib gets accelerated approval for KRAS G12C-mutated NSCLC

Jan 2023: Adagrasib (Krazati, Mirati Therapeutics, Inc.), a RAS GTPase family inhibitor, was given accelerated approval by the Food and Drug Administration (FDA) for adult patients with KRAS G12C-muta...
mirati-therapeutics

Scan the code